Evaluation of cisplatin-hydrogel for improving localized antitumor efficacy in gastric cancer

Qian, Keyang; Hu, Qian; Cai, Juan; Yue, Wuheng; Yu, Xiaoxiao; Liu, Baorui

doi:10.1016/j.prp.2019.01.005

Cited by 12 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They revealed that the activity of the examined complexes depends on the type of pyrazole ligand. It is said that the general action of cisplatin and its complexes are based on interacting with genetic material what in consequence leads to apoptosis [ 2 , 3 , 7 ]. In our study, we revealed that PtPz6 administrated with anti-MUC1 the most strongly induced apoptosis, as compared with controls, cisPt, anti-MUC1 as well as with both cisPt complexes used alone and PtPz4 combined with mAb.…”

Section: Discussionmentioning

confidence: 99%

“…Most of the GC patients are diagnosed with late stages, with poor prognosis and limited possibilities of effective therapies. Cisplatin, a common chemotherapeutic, is widely applied in the treatment of various human cancers [ 2 , 3 ]. Its action in cancer cells is based on the potential to crosslink with the DNA purine bases, attenuating DNA repair, leading to DNA damage, and consequently inducing apoptosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combined Action of Anti-MUC1 Monoclonal Antibody and Pyrazole-Platinum(II) Complexes Reveals Higher Effectiveness towards Apoptotic Response in Comparison with Monotherapy in AGS Gastric Cancer Cells

et al. 2021

View full text Add to dashboard Cite

MUC1 mucin is a transmembrane glycoprotein aberrantly overexpressed and underglycosylated in most epithelium origin cancers. Combining chemotherapeutics with monoclonal antibodies toward cancer-related antigens is one of the new strategies in cancer therapies. In this study, we assessed the effectiveness of 10 μM cisplatin (cisPt), two pyrazole-platinum(II) complexes (PtPz4 and PtPz6), and 5 μg/mL anti-MUC1 used as monotherapy, as well as cisplatin and its derivatives combined with mAb on apoptotic response and specific cancer-related sugar antigens in AGS gastric cancer cells. Flow cytometry, RT-PCR, Western blotting, and ELISA tests were applied to determine the influence of examined compounds on analyzed factors. PtPz6 combined with anti-MUC1 revealed the strongest apoptotic response compared to control and monotherapy. The combined action of both cisPt derivatives and anti-MUC1 was more effective than monotherapy in relation to Bad, Bcl-xL, Bcl-2, caspase-9, caspase-3, as well as pro- and cleaved caspase-3 protein, and T, sialyl Tn sugar antigens in cell lysates, and Tn, T, sialyl Tn, sialyl T antigens in culture medium. Additionally, PtPz4 administrated with mAb was revealed to be more potent than used alone with regard to Bax protein and Bid expression, and PtPz6 used in complex with anti-MUC1 revealed more efficient action towards Akt and sialyl T antigen expression. These data indicate the rationality of the potential application of combined treatment of anti-MUC1 and cisPt derivatives in gastric cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Combined Action of Anti-MUC1 Monoclonal Antibody and Pyrazole-Platinum(II) Complexes Reveals Higher Effectiveness towards Apoptotic Response in Comparison with Monotherapy in AGS Gastric Cancer Cells

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Aside from immunotherapy, we discovered an association between the patients' signatures and chemotherapy. Lowrisk patients were sensitive to first-line anticancer medicines (including etoposide, cisplatin, and gemcitabine) (Macdonald and Havlin, 1992;Qian et al, 2019;Sugisawa et al, 2020). Low-risk patients react better to chemotherapy and targeted medicines, which is crucial for tailored tumor treatments.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of antitumor drug targets prediction using integrated bioinformatic analysis for immunogenic cell death-related lncRNA model based on stomach adenocarcinoma characteristics and tumor immune microenvironment

Ding

Zhao

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Stomach adenocarcinoma (STAD) ranks as the fourth prevalent cause of mortality worldwide due to cancer. The prognosis for those suffering from STAD was bleak. Immunogenic cell death (ICD), a form of induced cellular death that causes an adaptive immune response and has increasing in anticancer treatment. However, it has not been ascertained how ICD-related lncRNAs affect STAD. Using univariate Cox regression and the TCGA database, lncRNAs with prognostic value were identified. Thereafter, we created a prognostic lncRNA-based model using LASSO. Kaplan-Meier assessment, time-dependent receiver operating characteristic (ROC) analyzation, independent prognostic investigation, and nomogram were used to assess model correctness. Additional research included evaluations of the immunological microenvironment, gene set enrichment analyses (GSEA), tumor mutation burdens (TMBs), tumor immune dysfunctions and exclusions (TIDEs), and antitumor compounds IC50 predictions. We found 24 ICD-related lncRNAs with prognostic value via univariate Cox analysis (p < 0.05). Subsequently, a risk model was proposed using five lncRNAs relevant to ICD. The risk signature, correlated with immune cell infiltration, had strong predictive performance. Individuals at low-risk group outlived those at high risk (p < 0.001). An evaluation of the 5-lncRNA risk mode including ROC curves, nomograms, and correction curves confirmed its predictive capability. The findings of functional tests revealed a substantial alteration in immunological conditions and the IC50 sensitivity for the two groups. Using five ICD-related lncRNAs, the authors developed a new risk model for STAD patients that could predict their cumulative overall survival rate and guide their individual treatment.

show abstract

“…Nanogels are three-dimensional cross-linked (physical and chemical bonds) network polymeric structures which can offer drug depot and controlled drug release for targeted drug delivery [67]. Nanogels possess a great tendency of water retention and are biocompatible and biodegradable.…”

Section: Nano Formulations Involved In Gemcitabine Co-administratimentioning

confidence: 99%

Gemcitabine Combination Nano Therapies for Pancreatic Cancer

et al. 2019

View full text Add to dashboard Cite

Pancreatic cancer is one of the deadliest causes of cancer-related death in the United States, with a 5-year overall survival rate of 6 to 8%. These statistics suggest that immediate medical attention is needed. Gemcitabine (GEM) is the gold standard first-line single chemotherapy agent for pancreatic cancer but, after a few months, cells develop chemoresistance. Multiple clinical and experimental investigations have demonstrated that a combination or co-administration of other drugs as chemotherapies with GEM lead to superior therapeutic benefits. However, such combination therapies often induce severe systemic toxicities. Thus, developing strategies to deliver a combination of chemotherapeutic agents more securely to patients is needed. Nanoparticle-mediated delivery can offer to load a cocktail of drugs, increase stability and availability, on-demand and tumor-specific delivery while minimizing chemotherapy-associated adverse effects. This review discusses the available drugs being co-administered with GEM and the limitations associated during the process of co-administration. This review also helps in providing knowledge of the significant number of delivery platforms being used to overcome problems related to gemcitabine-based co-delivery of other chemotherapeutic drugs, thereby focusing on how nanocarriers have been fabricated, considering the modes of action, targeting receptors, pharmacology of chemo drugs incorporated with GEM, and the differences in the physiological environment where the targeting is to be done. This review also documents the focus on novel mucin-targeted nanotechnology which is under development for pancreatic cancer therapy.

show abstract

Evaluation of cisplatin-hydrogel for improving localized antitumor efficacy in gastric cancer

Cited by 12 publications

References 14 publications

Combined Action of Anti-MUC1 Monoclonal Antibody and Pyrazole-Platinum(II) Complexes Reveals Higher Effectiveness towards Apoptotic Response in Comparison with Monotherapy in AGS Gastric Cancer Cells

Combined Action of Anti-MUC1 Monoclonal Antibody and Pyrazole-Platinum(II) Complexes Reveals Higher Effectiveness towards Apoptotic Response in Comparison with Monotherapy in AGS Gastric Cancer Cells

Prognostic value of antitumor drug targets prediction using integrated bioinformatic analysis for immunogenic cell death-related lncRNA model based on stomach adenocarcinoma characteristics and tumor immune microenvironment

Gemcitabine Combination Nano Therapies for Pancreatic Cancer

Contact Info

Product

Resources

About